Reduction of atherosclerotic events (MI, stroke or vascular death) in patients w/ atherosclerosis documented by recent stroke, MI, or established peripheral arterial disease. Patients suffering from non-ST segment elevation, acute coronary syndrome (unstable angina or non-Q wave MI) including patient undergoing stent placement following percutaneous coronary intervention or combination w/ ASA in medically treated patients eligible from thrombolytic therapy.
Acute coronary syndrome 300 mg loading dose, followed by 75 mg daily. Patient w/ non-ST segment elevation acute coronary syndrome Initially 300 mg loading dose & continued to 75 mg daily w/ ASA of not more than 100 mg to avoid the risk of bleeding. Patient w/ ST-segment elevation acute MI 75 mg single daily dose w/ loading dose of 300 mg in combination w/ ASA w/ or w/o thrombolytics. Elderly 75 yr Initially 75 mg. Patient w/ atrial fibrillation75 mg single dose daily in combination w/ ASA of doses 75-100 mg daily. Prophylaxis of thromboembolic events 75 mg once daily. Management of acute coronary syndromes, unstable angina & non-Q wave MI 300 mg loading dose, followed by 75 mg once daily.
Hematopoietic disorders eg, neutropenia or thrombocytopenia, hemorrhagic diathesis or other hemorrhagic disorders associated by a prolonged bleeding time or conditions w/ an increased risk of bleeding eg, GI ulcers, acute cerebral hemorrhage or severe liver dysfunction. Perform full blood counts before starting treatment & every 2 wk during 1st 3 mth of therapy. Discontinue therapy 10-14 days before elective surgery. Thrombotic thrombocytopenic purpura may occur after a short exposure (<2 wk). Discontinue when manifestation of acquired hemophilia occurs.
Potentiates the effect of aspirin on collagen-induced platelet aggregation. Risk of increased occult GI blood loss w/ NSAIDs. May interfere w/ the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin.
Sign Out
